Table 1.
Demographics of all randomized patients
| Characteristic | Placebo (n=97) | PAR/VAL (n=98) |
|---|---|---|
| Age, years | ||
| Mean (SD) | 45.7 (10.1) | 47.1 (9.9) |
| Range | 25–78 | 28–79 |
| Sex, n (%) | ||
| Male | 1 (1.0) | 1 (1.0) |
| Female | 96 (99.0) | 97 (99.0) |
| Race, n (%) | ||
| White | 73 (75.3) | 82 (83.7) |
| Black | 14 (14.4) | 14 (14.3) |
| Asian | 0 (0.0) | 1 (1.0) |
| Not listed | 10 (10.3) | 1 (1.0) |
| BMI, Kg/m2 | ||
| Mean (SD) | 27.6 (5.4) | 26.8 (4.6) |
| Procedure, n (%) | ||
| Uterine | 47 (48.5) | 50 (51.0) |
| Adnexa | 3 (3.1) | 6 (6.1) |
| Other | 12 (12.4) | 9 (9.2) |
| Uterine/other | 7 (7.2) | 5 (5.1) |
| Adnexa/other | 1 (1.0) | 0 (0.0) |
| Uterine/adnexa | 26 (26.8) | 28 (28.6) |
| Uterine/adnexa/other | 1 (1.0) | 0 (0.0) |
Abbreviations: PAR/VAL, parecoxib/valdecoxib; SD, standard deviation; BMI, body mass index.